World J Mens Health.  2015 Dec;33(3):123-124. 10.5534/wjmh.2015.33.3.123.

Evolution of Phosphodiesterase-5 Inhibitors

• Moon DG

• KMID: 2405139
• DOI: http://doi.org/10.5534/wjmh.2015.33.3.123

Abstract

No abstract available.

MeSH Terms

Cyclic Nucleotide Phosphodiesterases, Type 5*
Cyclic Nucleotide Phosphodiesterases, Type 5

Reference

1. Ryu JK, Cho KS, Kim SJ, Oh KJ, Kam SC, Seo KK, et al. Korean Society for Sexual Medicine and Andrology (KSSMA) guideline on erectile dysfunction. World J Mens Health. 2013; 31:83–102.

2. Ahn TY, Lee SW, Kim SW, Yang DY, Park NC, Min KS, et al. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. Asian J Androl. 2007; 9:760–770.

3. Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008; 65:848–854.

4. Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, et al. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health. 2014; 32:18–27.

5. Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, et al. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int. 2012; 110:1801–1806.

6. Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health. 2013; 31:193–207.

7. Smith WB 2nd, McCaslin IR, Gokce A, Mandava SH, Trost L, Hellstrom WJ. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013; 67:768–780.